Megakaryocyte Heterogeneity in Sickle Cell Disease

ConditionSickle Cell Disease (SCD)

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorCentre Hospitalier Universitaire de la Guadeloupe

About this trial

Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis (VOC) and chronic inflammation. Activated platelets of SCD patients participated to both chronic inflammation and painful VOC. Platelets are anucleated cells from the fragmentation of megakaryocytes in bone marrow.

The main aim of this study is to characterize the distribution of the different megakaryocyte subpopulations of sickle cell disease patients SS and SC and in particular the "immune" megakaryocytes CD148+CD48+ and to compare it with the platelet phenotype.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

patients with SS or SC SCD

diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies

patients older than 18 years at inclusion

clinically in a steady state at inclusion (without complication in the last month and without transfusion in the three last months)

Disqualifiers

patients younger than 18 years old

patients with hemoglobinopathy other than SS and SC SCD

patients with a transfusion therapy or on bleeding therapy for less than three months

patients no affiliated to national social security

Trial population

Patients with sockle celle disease are patients who come for their disease. Control group are patients who come at the University hospital of Guadeloupe (Pointe à Pitre), for hip or knee replacement and will do not suffer from chronic disease.

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

100 Participants

are grouped into 3 trial groups

Group A: SS patients

Group B: SC patients

Group C: control group AA

Trial outcomes

Primary outcomes

proportion of immune megakaryocytes CD148+CD48+ in bone marrow

The primary outcome will be the evaluation of the proportion of immune megakaryocytes CD148+CD48+ in bone marrow of sickle cell disease patients in comparison to control group.

Time frame

24 months

Secondary outcomes

platelet phenotype

The secondary outcomes are to compare the platelet phenotype between the three groups of patients, including the proportion of CD148+CD48+ platelets, to study the activation of this platelet subpopulation (expression of CD62P) and establish whether there is a relationship between the proportion of immune megakaryocytes in the bone marrow and the proportion of CD148+CD48+ platelets in the blood.

Time frame

24 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Centre Hospitalier Universitaire de la Guadeloupe

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: